These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 605911

  • 1. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
    Case DC, Lee DJ, Clarkson BD.
    Am J Med; 1977 Dec; 63(6):897-903. PubMed ID: 605911
    [No Abstract] [Full Text] [Related]

  • 2. Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU.
    Lee BJ, Sahakian G, Clarkson BD, Krakoff IH.
    Cancer; 1974 Feb; 33(2):533-8. PubMed ID: 4812771
    [No Abstract] [Full Text] [Related]

  • 3. Combination therapy for multiple myeloma.
    Alexanian R, Salmon S, Bonnet J, Gehan E, Haut A, Weick J.
    Cancer; 1977 Dec; 40(6):2765-71. PubMed ID: 589554
    [Abstract] [Full Text] [Related]

  • 4. Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.
    Steinke B, Busch FW, Becherer C, Ostendorf P, Waller HD.
    Cancer Chemother Pharmacol; 1985 Dec; 14(3):279-81. PubMed ID: 3838922
    [Abstract] [Full Text] [Related]

  • 5. Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma.
    Presant CA, Klahr C.
    Cancer; 1978 Sep; 42(3):1222-7. PubMed ID: 698913
    [Abstract] [Full Text] [Related]

  • 6. Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).
    Case DC, Sonneborn HL, Paul SD, Hayes DM, Dorsk BM, Carroll RJ, Bove L.
    Oncology; 1985 Sep; 42(3):137-40. PubMed ID: 3858763
    [Abstract] [Full Text] [Related]

  • 7. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [Abstract] [Full Text] [Related]

  • 8. [Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
    Iwata Y, Karitani Y, Tanaka I, Kobayashi T, Ohno T, Kageyama S, Katayama N, Kataoka Y, Kamio N, Ohota C.
    Rinsho Ketsueki; 1984 Sep; 25(9):1380-7. PubMed ID: 6549187
    [No Abstract] [Full Text] [Related]

  • 9. [Chemotherapy of multiple myeloma. Review of the recent trials].
    Tribalto M, Arcese W, Colombo R, Pastore S, Franchii A.
    Recenti Prog Med; 1981 Aug; 71(2):141-7. PubMed ID: 7031807
    [No Abstract] [Full Text] [Related]

  • 10. Combination chemotherapy (M-2) protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for Waldenström macroglobulinemia: preliminary report.
    Case DC.
    Blood; 1982 May; 59(5):934-7. PubMed ID: 6803856
    [Abstract] [Full Text] [Related]

  • 11. Treatment of multiple myeloma: a randomized study of three different regimens.
    Tribalto M, Amadori S, Cantonetti M, Franchi A, Papa G, Pileri A, Boccadoro M, Dammacco F, Vacca A, Centurioni R.
    Leuk Res; 1985 May; 9(8):1043-9. PubMed ID: 3900591
    [Abstract] [Full Text] [Related]

  • 12. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U, Crivellari D, Carbone A, Veronesi A, Galligioni E, Trovò MG, Tumolo S, Grigoletto E.
    Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
    [Abstract] [Full Text] [Related]

  • 13. Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.
    Buonanno G, Tortarolo M, Valente A, Castaldo C, Russolillo S, Gonnella F.
    Haematologica; 1978 Feb; 63(1):45-55. PubMed ID: 417971
    [No Abstract] [Full Text] [Related]

  • 14. [Treatment of Kahler's disease].
    Foa J, Carcassonne Y.
    Sem Hop; 1976 Jan 16; 52(3):165-71. PubMed ID: 186874
    [No Abstract] [Full Text] [Related]

  • 15. The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93.
    Kyle RA, Jacobus S, Friedenberg WR, Slabber CF, Rajkumar SV, Greipp PR.
    Cancer; 2009 May 15; 115(10):2155-64. PubMed ID: 19248045
    [Abstract] [Full Text] [Related]

  • 16. Prognosis of myelomatosis on treatment with prednisone and cytostatics.
    Hansen OP, Jessen B, Videbaek A.
    Scand J Haematol; 1973 May 15; 10(4):282-90. PubMed ID: 4764610
    [No Abstract] [Full Text] [Related]

  • 17. M-2 protocol for melphalan-resistant and relapsing multiple myeloma.
    Cavo M, Galieni P, Tassi C, Gobbi M, Tura S.
    Eur J Haematol; 1988 Feb 15; 40(2):168-73. PubMed ID: 3345830
    [Abstract] [Full Text] [Related]

  • 18. [Recent progress in chemotherapy of multiple myeloma].
    Tortarolo M, Cantore N, Russolillo S, Castaldo C, Buonanno G.
    Recenti Prog Med; 1978 Jul 15; 65(1):44-68. PubMed ID: 370935
    [No Abstract] [Full Text] [Related]

  • 19. An overview of the status of the nitrosoureas in other tumors.
    Carter SK.
    Cancer Chemother Rep 3; 1973 May 15; 4(3):35-46. PubMed ID: 4584034
    [No Abstract] [Full Text] [Related]

  • 20. Plasma cell myeloma. An interpretive review.
    Bergsagel DE.
    Cancer; 1972 Dec 15; 30(6):1588-94. PubMed ID: 4565818
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.